Eli Lilly surged 58% in 2024, driven by weight-loss drugs and strong earnings. The technical chart shows consolidation. See ...

Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...

Netflix and Eli Lilly lead this weekend's list of five stocks near buy points that are all enjoying rapid sales growth.

Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...

This is thanks to Lilly's dominance in the billion-dollar weight loss drug market. Lilly's Mounjaro and Zepbound have helped ...

The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Eli Lilly & Co. is asking people who took copies of its blockbuster weight loss drug to give the company access to their ...

Eli Lilly appeals a $183 million judgment in a Medicaid fraud case, arguing that it followed a reasonable interpretation of ...

Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...

Shares of Eli Lilly & Co. LLY slipped 1.88% to $906.18 Tuesday, on what proved to be an all-around mixed trading session for ...

The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...